- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00111228
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
Randomised, Controlled, Multi-centric, Clinical Study to Assess Whether Type 1 Diabetic Patients in Poor Glycemic Control Can Improve Using the Real-time Values of Guardian T Versus Conventional Self-Monitoring Blood Glucose
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Finger-stick based self-testing (SBGM), as well as diagnostic continuous glucose monitoring (CGMS®) allow diabetic patients to find a balance between the two hyper- and hypoglycemic extremes. Nevertheless, there are still patients who fail to achieve good control due to fear of hypoglycemia, or who underestimate post-prandial hyperglycemias.
The Guardian® RT Telemetered Glucose Monitoring System is indicated for continuous or periodic monitoring of real-time interstitial blood glucose values and low/high blood glucose alarms (when pre-set levels are reached) in persons with diabetes mellitus. The glucose values calculated by the device will be used to trigger hypo- and hyperglycemia alerts and will be displayed every 5 minutes. The Guardian® RT stores up to 21 days of data.
The overall primary objective of the study is to determine whether patients with poor glycemic control as evidenced by HbA1c > 8.1% can achieve improved metabolic control using the real-time values of the Guardian® RT compared to conventional self-monitoring blood glucose finger-sticks (control group) after 12 weeks of continuous use.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Corbeil Esssonnes, France, 91106
- Hôpital Sud Francilien
-
Paris, France, 75019
- CH Robert Debre
-
-
-
-
-
Berlin, Germany, D-13353
- Klinik für Allgemeine Charité, CVK
-
-
-
-
-
Petah Tikva, Israel, 49202
- Schneider Children Centre
-
-
-
-
-
Milano, Italy, 20132
- Universita Vita-Salute OspedaleS.Raffaele
-
-
-
-
-
Ljubljana, Slovenia, SI-1525
- University Children's Hospital
-
-
-
-
-
Huddinge, Sweden, SE-141 86
- Huddinge University Hospital
-
-
-
-
-
Bournemouth, United Kingdom, Dorset BH7 7DW
- Royal Bournemouth Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has signed Informed consent form prior to Study Entry.
- Patients have been diagnosed with type 1 diabetes mellitus (DM) at least 12 months prior to Study Entry.
- HbA1c must be 8.1% or above at study entry day (central lab value).
- Patients must perform at least two self-monitoring blood glucose finger-sticks daily.
- Patients are on intensive insulin therapy; for multiple daily injections (MDI) patients specifically, be on a schedule of a minimum of 3 injections daily.
- Patients on intensive insulin therapy must be on continuous subcutaneous insulin infusion (CSII) or MDI at least 3 months prior to inclusion and should have been receiving diabetes care from the investigator of each centre for the 6 months prior to inclusion.
- Patients must be using only insulin analogues or rapid-acting human insulin for their meal boluses.
- Patients are willing to undergo all study procedures.
- Patients are trained on how to adapt their insulin dose to their meals and are knowledgeable concerning how to calculate and apply corrective insulin boluses post-prandially, as well as on the influence of physical activity and other life style factors on their glycemia.
- Patients are willing to participate in a Guardian® RT product training course
- Patients understand how to adjust and administer corrective treatment.
Exclusion Criteria:
- Patient has hearing problems/is deaf.
- Patient has impaired vision/blindness so screen alarms cannot be recognized.
- Alcohol or drug abuse other than nicotine.
- Allergy to sensor or components of the sensor.
- Manifest psychiatric disturbances.
- Patients suffering from cancer, heart failure, kidney disease and other chronic debilitating conditions.
- Patient does not have a reliable support person.
- Patient is unwilling or unable to comply with the provisions of the protocol.
- Patient has scheduled travel on a plane in the next 3 months.
- Patient has scheduled a vacation which will occur between Visit 1 and Visit 2.
- Patient is participating in another device or drug study. Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. The subject may only be enrolled in this study once. Patient has already participated in the Centre Qualification Phase.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Continuous use of the Guardian RT
Continuous use of the Guardian RT group
|
|
Experimental: Bi-weekly use of the Guardian RT (once every 2 weeks)
Bi-weekly use of the Guardian RT (once every 2 weeks) group
|
|
Active Comparator: Control group. SMBG monitoring
Control group.
SMBG monitoring group
|
SMBG only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c (HbA1c) - Change From Baseline to End of 3 Month Study Period
Time Frame: baseline and 3 month after study
|
Hemoglobin A1c (HbA1c) - change from baseline to end of 3 month study period, calculated as A1c at 3 month - A1c at baseline
|
baseline and 3 month after study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Blood Glucose - Change From Baseline to End of 3 Month Study Period, Calculated as Average Blood Glucose at 3 Month - Average Blood Glucose at Baseline
Time Frame: baseline and 3 month after study
|
Average blood glucose - change from baseline to end of 3 month study period, calculated as average blood glucose at 3 month - average blood glucose at baseline
|
baseline and 3 month after study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dorothee Deiss, MD, Klinik für Allgemeine Charité, CVK
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EU 007_022004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Clinical Trials on Guardian RT
-
Medical University of GrazCompleted
-
Medtronic DiabetesCompletedType 1 Diabetes MellitusSlovenia, United Kingdom, France, Germany, Israel, Italy, Sweden
-
Korea UniversityCompletedType 2 DiabetesKorea, Republic of
-
Sheba Medical CenterUnknownDiabetes MellitusIsrael
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHealthy | Type 1 Diabetes | Hypoglycemia UnawarenessUnited States
-
University Hospital PadovaUniversity of PadovaRecruitingInfant Development | Neurodevelopmental Abnormality | Hypoglycemia NeonatalItaly
-
Medtronic DiabetesCompletedType 1 Diabetes Mellitus | Type2 Diabetes MellitusUnited States
-
Istituto Nazionale di Ricovero e Cura per AnzianiEuropean CommissionCompletedCaregiver | Aging ProblemsItaly, Netherlands, Switzerland
-
TurnCare Inc.UnknownIschemic StrokeUnited States
-
University of AlbertaCompleted